The BAG1 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma A-549 cell line, featuring targeted disruption of the BAG1 gene. This loss-of-function model is designed for researchers investigating BAG1-dependent mechanisms in apoptosis, protein quality control, and oncogenic signaling. The polyclonal format preserves a heterogeneous knockout background, offering a representative population for functional studies without clonal selection artifacts. As a genetic tool, it enables the systematic interrogation of BAG1’s role in cellular homeostasis and disease-relevant pathways.
The host A-549 cell line is an extensively characterized human lung adenocarcinoma model, originally isolated from a 58-year-old Caucasian male. These adherent epithelial cells harbor a KRAS G12S mutation and wild-type p53, making them a standard system for non-small cell lung cancer (NSCLC) research. A-549 cells are widely employed to study tumorigenesis, epithelial-mesenchymal transition, and drug sensitivity, owing to their robust proliferation and reproducible behavior. Their use in apoptosis and stress response assays further establishes them as a suitable background for investigating BAG1-mediated cytoprotective processes.
BAG1 encodes a multifunctional co-chaperone that modulates Hsp70/Hsc70 activity, directly influencing protein folding and anti-apoptotic pathways. Mechanistically, BAG1 stabilizes BCL2 and activates the Raf-1/MEK/ERK pro-survival signaling cascade, while also interacting with the 26S proteasome to regulate protein degradation. Upstream, BAG1 is induced by HSF1 under heat shock, oxidative stress, and ER stress conditions. Downstream targets include BCL2, Hsp70, and the ubiquitin-proteasome system, linking BAG1 to mitochondrial integrity and proteostasis. The pathway is further integrated through interactions with androgen and estrogen receptors, highlighting BAG1’s role in cross-talk between stress responses and proliferative signaling.
Disruption of BAG1 in A-549 cells creates a critical model for dissecting its contribution to lung adenocarcinoma chemoresistance and survival. Given that BAG1 overexpression is associated with poor prognosis in multiple cancers, this knockout tool enables precise assessment of its function in tumor cell adaptation to therapeutic stress. By abrogating BAG1, researchers can evaluate the consequent effects on BCL2 stability, Raf-1 signaling, and proteasomal activity, thereby elucidating how co-chaperone networks sustain malignancy. This model is particularly valuable for screening compounds that target Hsp70 chaperone machinery or downstream effector pathways.
This polyclonal knockout cell population supports a wide range of experimental applications, including apoptosis assays (annexin V staining, caspase-3 cleavage analysis), chemosensitivity profiling, and co-immunoprecipitation of BAG1 interactors. Additionally, it is suitable for western blotting, RT-qPCR, flow cytometry, and protein aggregation assays to monitor proteostasis. Representative uses encompass drug resistance studies with cisplatin or gefitinib, stress response kinetics under proteotoxic insults, and validation of BAG-1-dependent signaling nodes such as MEK/ERK phosphorylation. For further technical specifications or customized inquiries, please contact Ascent Research.
